Citadel Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Citadel Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$741K	Buy	7,600 +900	+13%	+$78.6K	﹤0.01%	8928
2026 Q1	$562K	Buy	+6,700	New	+$388K	﹤0.01%	9020
2025 Q4	–	Sell	-29,700	Closed	-$1.17M	–	12910
2025 Q3	$1.17M	Buy	+29,700	New	+$759K	﹤0.01%	7195
2025 Q2	–	Sell	-100	Closed	-$1.81K	–	13053
2025 Q1	$1.81K	Sell	100 -300	-75%	-$6.61K	﹤0.01%	14095
2024 Q4	$8.72K	Hold	400	–	–	﹤0.01%	13675
2024 Q3	$11K	Buy	+400	New	+$11.1K	﹤0.01%	13177
2023 Q4	–	Sell	-276	Closed	-$3.77K	–	14446
2023 Q3	$3.77K	Sell	276 -605	-69%	-$7.62K	﹤0.01%	13550
2023 Q2	$10.7K	Sell	881 -50	-5%	-$569	﹤0.01%	13186
2023 Q1	$11.8K	Sell	931 -682	-42%	-$7.55K	﹤0.01%	13453
2022 Q4	$10.2K	Buy	+1,613	New	+$28.6K	﹤0.01%	13640
2021 Q4	–	Sell	-738	Closed	-$86K	–	13957
2021 Q3	$86K	Buy	+738	New	+$86K	﹤0.01%	13007

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Citadel Advisors's DNTH Position: Q2 2026 in Review

Citadel Advisors reduced its Dianthus Therapeutics (DNTH) stake by 39% in Q2 2026, selling an estimated $55.5M and leaving 974,911 shares worth $95M. The position accounts for 0.01% of the portfolio, ranked #1007.

Citadel Advisors first reported a position in DNTH in Q2 2018 and has held it in 27 quarters since. The position peaked at $135M in Q1 2026. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Citadel Advisors held 974,911 shares of Dianthus Therapeutics worth $95M as of Q2 2026.
Citadel Advisors sold 635,572 Dianthus Therapeutics shares in Q2 2026, an estimated $55.5M.
Dianthus Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #1007 holding.
Citadel Advisors first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 27 quarters since.
Citadel Advisors's Dianthus Therapeutics position peaked at $135M in Q1 2026.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.